Research institution
The Methodist Hospital Research Institute Clinical Trials
Studies where The Methodist Hospital Research Institute is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 57Ureteral Stent-Related Symptom
Dexamethasone for Ureteral STent Symptoms (DUSTS)
The purpose of this study to learn if high-dose dexamethasone, a type of long-acting steroid, works to decrease urinary symptoms and pain after ureteroscopy and stent placement for kidney stones.
- Trial name
- DUSTS (NCT06930690)
- Testing
- Dexamethasone Sodium Phosphate Injection 20 mg, Dexamethasone Sodium Phosphate Injection 4mg
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Methodist Hospital Research Institute
Spinal Cord Injuries, Cervical Spinal Cord Injury
Augmenting Upper Limb Function and Functional Neuroplasticity Using Epidural Stimulation of the Cervical Spinal Cord
This study will test whether spinal stimulation combined with rehabilitation can improve arm and hand function in people with tetraplegia after spinal cord injury. Tetraplegia causes weakness or paralysis in the arms and legs.
- Conditions
- Spinal Cord Injuries, Cervical Spinal Cord Injury, Spinal Cord Injury
- Trial name
- NCT06225245
- Testing
- Epidural Spinal Stimulation (ESS), Upper extremity rehabilitation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are undergoing evaluation for or waitlisted for liver transplantation will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus…
- Trial name
- NCT05185505
- Testing
- Atezolizumab, Bevacizumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- The Methodist Hospital Research Institute
Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease…
- Trial name
- NCT07060001
- Testing
- 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Non-Small-Cell Lung
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative…
- Trial name
- NCT06566443
- Testing
- Honokiol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Methodist Hospital Research Institute
Advanced or Metastatic CRC
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
This is a phase I study investigating the safety and antitumor activity of 5FU-based therapy (FOLFIRI/FOLFOX + Biologics) in combination with Hydroxytyrosol (HT) as a treatment for patients with advanced or metastatic colorectal…
- Trial name
- NCT06833866
- Testing
- Hydroxytyrosol
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Colorectal Cancer (CRC)
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.
- Trial name
- NCT06887218
- Testing
- Regorafenib (BAY 73-4506), 5FU/LV, Bevacizumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1…
- Conditions
- Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer
- Trial name
- SWIFT (NCT07820358)
- Testing
- Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- The Methodist Hospital Research Institute
Advanced Small Intestine Cancer, Appendiceal Cancers
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
This study will evaluate the safety and efficacy of NALIRIFOX per NAPOLI-3 regimen as first-line chemotherapy for patients with advanced small intestine and appendiceal cancers.
- Trial name
- NCT07060014
- Testing
- Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- The Methodist Hospital Research Institute
Alzheimer Dementia (AD)
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Trial name
- NCT07651319
- Testing
- IL-2 (Aldesleukin), Semaglutide Plus IL-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Completed, with results posted
All 26ALS (Amyotrophic Lateral Sclerosis)
T-regulatory Cells in ALS
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same…
- Trial name
- Tregs in ALS (NCT04055623)
- Testing
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
ALS (Amyotrophic Lateral Sclerosis)
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
- Trial name
- NCT03241784
- Testing
- Autologous T-regulatory lymphocytes, Interleukin-2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Methodist Hospital Research Institute
Virtual Reality
Usability, Acceptability, and Safety of Virtual Reality-based Cognitive Intervention
This study aims to determine feasibility, acceptability, and usability, and to assess the safety of using a virtual reality-based software called ''ReCognitionVR'' in healthy volunteers.
- Trial name
- NCT05583903
- Testing
- Virtual Reality Software
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Chemotherapy-induced Peripheral Neuropathy
Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy
This study will determine the feasibility and efficacy of a 10-treatment electro-acupuncture (EA) program in subjects with chemotherapy-induced peripheral neuropathy (CIPN).
- Trial name
- NCT07455409
- Testing
- Electro-acupuncture
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute